Opdivo Qvantig (nivolumab/hyaluronidase-nvhy) is a prescription drug used to treat certain types of cancer. Opdivo Qvantig comes as a liquid that’s injected under your skin. Opdivo Qvantig is used in ...
The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved median ...
Nivolumab and ipilimumab combination approved for microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC), showing significant progression-free ...
Perioperative nivolumab not only extends event-free survival (EFS) but also does not compromise quality of life in patients with resectable non-small cell lung cancer (NSCLC), including those with ...
Immune landscape in lung cancer: Lymphocyte subsets as potential predictors of treatment outcomes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...
The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for the treatment of adults and children aged 12 years ...
A groundbreaking study from Tata Memorial Hospital shows that using ultra-low doses of nivolumab, an immunotherapy drug, can effectively treat cancer while drastically reducing costs by 90%. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results